The article discusses a study on the efficacy of atovaquone as a Pneumocystis carinii pneumonia (PCP) prophylactic agent in pediatric patients with leukemia. Only patients who were intolerant of trimethoprim-sulfamethoxazole (TMP-SMZ) and received alovaquone prophylaxis were included in the analysis.